Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study
Gritstone Oncology launched one of the most prominent neoantigen R&D efforts in the industry with a $102 million mega-round two years ago. And now the biotech is lining up its first big clinical foray — while laying the foundation for an eventual market launch — with another mega-round that weighs in at $92.7 million.
This biotech is a prime example of the venture community’s willingness to go deep and long in an attempt to deliver a leading company in the hunt for new technologies to fight life-threatening diseases. And part of that gamble includes constructing new manufacturing facilities that can support the development of personalized therapies — a blueprint that Gritstone is committed to.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.